Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study

Nimatoudis, Ioannis; Zissis, NP; Kogeorgos, J.; Theodoropoulou, St.; Vidalis, A; Kaprinis, George

doi:10.1097/00004850-200411000-00003

Cited by 43 publications

(20 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, remission rate (HAM‐A score ≤7) was 33.3% in the VTG and 36.0% in the PTG at the end‐point, respectively. These positive results for efficacy in both groups are in accordance with other previous studies 11–14 . Overall, the response rates and remission rates in the VTG and PTG were higher than in those of the placebo treatment group in the previous controlled studies with venlafaxine XR and paroxetine, respectively, 12,14 suggesting that both agents may be effective and tolerable for the treatment of GAD.…”

Section: Discussionsupporting

confidence: 90%

Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder

Kim

Pae

Yoon

et al. 2006

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

This trial was to evaluate the efficacy and tolerability of venlafaxine extended release (XR) and paroxetine for treatment of patients with generalized anxiety disorder (GAD). Sixty patients who met DSM-IV criteria for GAD were randomly assigned to either venlafaxine XR or paroxetine for 8 weeks. Efficacy was assessed with the Hamilton Rating Scale for Anxiety (HAM-A) and Clinical Global Impression-Severity of Illness (CGI-S) scale at the baseline, week 1, week 4, and week 8. The side-effects were collected with reported adverse events and laboratory tests throughout the study period. Repeated measures analysis of variance ( anova ) on the HAM-A and CGI-S scores showed a significant decrease over time in both treatment groups without significant group difference or time × group interaction effect. There were no serious adverse events in both groups. This open trial demonstrated that either venlafaxine XR or paroxetine would be effective and tolerable for the treatment of patients with GAD. Double blind, placebo-controlled head-to-head comparison studies are needed to draw a definite conclusion.

show abstract

Section: Discussionsupporting

confidence: 90%

Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder

Kim

Pae

Yoon

et al. 2006

Psychiatry Clin Neurosci

View full text Add to dashboard Cite

show abstract

“…Response rates of 73% and remission rates of 41% also compare favorably with other studies of psychotherapy and pharmacotherapy. [6768]…”

Section: Discussionmentioning

confidence: 99%

A multicomponent yoga-based, breath intervention program as an adjunctive treatment in patients suffering from generalized anxiety disorder with or without comorbidities

et al. 2012

View full text Add to dashboard Cite

Objectives:The aim of this study is to evaluate the efficacy and tolerability of Sudarshan Kriya Yoga (SKY) course in generalized anxiety disorder (GAD) outpatients, who after eight weeks of an appropriate dose of traditional therapy had not yet achieved remission.Subjects:The adult participants (18-65 years) were outpatients with a primary diagnosis of GAD with or without comorbidities on the Mini-International Neuropsychiatric Interview (MINI). Participants had a minimum of eight weeks standard treatment with an appropriate dose of a standard prescription anxiolytic, a clinician global impression-severity (CGI-S) score of 5-7, a Hamilton anxiety scale (HAM-A) total score ≥20 including a score of >2 on the anxious mood and tension items.Materials and Methods:Forty-one patients were enrolled in an open-label trial of the SKY course as an adjunct to standard treatment of GAD at the START Clinic for Mood and Anxiety Disorders, a tertiary care mood and anxiety disorder clinic in Toronto. The SKY course was administered over five days (22 h total). Subjects were encouraged to practice the yoga breathing techniques at home for 20 min per day after the course and were offered group practice sessions for 2 h once a week led by certified yoga instructors. The primary outcome measure was the mean change from pre-treatment on the HAM-A scale. Psychological measures were obtained at baseline and four weeks after completing the intervention.Results:Thirty-one patients completed the program (mean age 42.6 ± 13.3 years). Among completers, significant reductions occurred in the pre- and post-intervention mean HAM-A total score (t=4.59; P<0.01) and psychic subscale (t=5.00; P≤0.01). The response rate was 73% and the remission rate 41% as measured on the HAM-A.Conclusion:The results of this small pilot trial suggest that the SKY course represents a potentially valuable adjunct to standard pharmacotherapy in patients with GAD or treatment-resistant GAD, and warrants further investigation. In particular, changes in worry and body symptoms showed significant improvements that may further our understanding of the mechanism of change in the tolerance of anxiety and worry.

show abstract

“…Á Venlafaxine was superior to placebo (LenoxSmith and Reynolds 2003;Nimatoudis et al 2004;Rickels et al 2000b). In comparator studies, it was more effective than placebo and as effective as pregabalin (Montgomery et al 2006b) and duloxetine (Hartford et al 2007;Nicolini et al 2008).…”

Section: Generalized Anxiety Disorder (Gad)mentioning

confidence: 97%

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Bandelow

Zohar

Hollander

et al. 2008

The World Journal of Biological Psychiatry

718

410

View full text Add to dashboard Cite

In this report, which is an update of a guideline published in 2002 (Bandelow et al. 2002, recommendations for the pharmacological treatment of anxiety disorder, obsessive-compulsive disorder (OCD) and post-traumatic stress disorder (PTSD) are presented. Since the publication of the first version of this guideline, a substantial number of new randomized controlled studies of anxiolytics have been published. In particular, more relapse prevention studies are now available that show sustained efficacy of anxiolytic drugs. The recommendations, developed by the World Federation of Societies of Biological Psychiatry (WFSBP) Task Force for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders, a consensus panel of 30 international experts, are now based on 510 published randomized, placebo-or comparator-controlled clinical studies (RCTs) and 130 open studies and case reports. First-line treatments for these disorders are selective serotonin reuptake inhibitors (SSRIs), serotonin-noradrenaline reuptake inhibitors (SNRIs) and the calcium channel modulator pregabalin. Tricyclic antidepressants (TCAs) are equally effective for some disorders, but many are less well tolerated than the SSRIs/ SNRIs. In treatment-resistant cases, benzodiazepines may be used when the patient does not have a history of substance abuse disorders. Potential treatment options for patients unresponsive to standard treatments are described in this overview. Although these guidelines focus on medications, non-pharmacological were also considered. Cognitive behavioural therapy (CBT) and other variants of behaviour therapy have been sufficiently investigated in controlled studies in patients with anxiety disorders, OCD, and PTSD to support them being recommended either alone or in combination with the above medicines.

show abstract

Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study

Cited by 43 publications

References 5 publications

Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder

Comparison of venlafaxine extended release versus paroxetine for treatment of patients with generalized anxiety disorder

A multicomponent yoga-based, breath intervention program as an adjunctive treatment in patients suffering from generalized anxiety disorder with or without comorbidities

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision

Contact Info

Product

Resources

About